Raynaud's: What Could Be Causing It?

What Raynaud's Phenomenon Actually Is

Raynaud's phenomenon is an exaggerated vasospastic response in the digital arteries and arterioles, triggered by cold exposure or emotional stress. The classic triphasic color change (white to blue to red) reflects ischemia, deoxygenation, and reperfusion in sequence. An estimated 3 to 5% of the global population experiences these episodes [1].

The distinction between primary and secondary Raynaud's determines the clinical trajectory. Primary Raynaud's (previously called Raynaud's disease) accounts for roughly 90% of cases and carries no tissue damage risk [2]. Secondary Raynaud's (Raynaud's phenomenon associated with an underlying condition) can progress to digital ulceration, gangrene, and autodigital amputation. The separation matters because secondary Raynaud's demands a different treatment intensity and long-term surveillance strategy.

Pathophysiology centers on an imbalance between vasoconstriction and vasodilation at the level of the digital microvasculature. Endothelin-1, a potent vasoconstrictor, is elevated in secondary forms, while nitric oxide bioavailability drops [3]. Alpha-2 adrenergic receptor hypersensitivity amplifies the cold response in both forms. These molecular details explain why calcium channel blockers and phosphodiesterase-5 inhibitors work as therapies. They also explain why the condition worsens in cold climates and improves in warm ones.

Primary Raynaud's: The Benign Majority

Primary Raynaud's typically presents in women between ages 15 and 25, with symmetric involvement of both hands. There is no tissue necrosis. No digital pitting scars. Normal nailfold capillaries under dermoscopy. A 2003 population-based study in Framingham found that among 4,182 participants, 11.8% of women and 8.1% of men reported Raynaud's-type symptoms, with the vast majority having no associated connective tissue disease [4].

The diagnostic criteria for primary Raynaud's, as defined by LeRoy and Medsger in 1992, require symmetric attacks with no evidence of peripheral vascular disease, no tissue necrosis, normal nailfold capillaries, negative ANA, and a normal erythrocyte sedimentation rate (ESR) [5]. Meeting all five criteria effectively rules out secondary causes with high confidence.

Genetic susceptibility plays a role. A genome-wide association study published in Nature Communications in 2023 (N=5,147 cases) identified several loci associated with primary Raynaud's, including ADRA2A (the alpha-2A adrenergic receptor gene) and IRX1, a transcription factor involved in vascular development [6]. This finding confirmed the long-suspected link between adrenergic receptor biology and Raynaud's at the genomic level.

Family history is present in roughly 25 to 30% of primary cases. Smoking worsens attack frequency and severity in both primary and secondary forms. Caffeine may trigger episodes in sensitive individuals, though evidence for universal caffeine restriction is thin.

Secondary Raynaud's: The Conditions That Cause It

Secondary Raynaud's signals an underlying pathology. The differential is broad, but connective tissue diseases dominate. Systemic sclerosis (scleroderma) is the single most common cause, with Raynaud's present in over 95% of scleroderma patients and often preceding skin thickening by years [7].

Autoimmune and Connective Tissue Diseases

Scleroderma deserves the most clinical attention. The EUSTAR registry (European Scleroderma Trials and Research group, N=14,524) documented that Raynaud's was the initial symptom in 73% of systemic sclerosis patients, appearing a median of 4.8 years before diagnosis [8]. Digital ulcers developed in approximately 50% of these patients over their disease course.

Other autoimmune causes include:

• Systemic lupus erythematosus (SLE): Raynaud's occurs in 10 to 45% of lupus patients, often alongside anti-U1 RNP antibodies [9].
• Mixed connective tissue disease (MCTD): Raynaud's is present in nearly 90% of MCTD cases and is a defining feature of the condition.
• Dermatomyositis and polymyositis: Raynaud's affects roughly 20 to 30% of inflammatory myopathy patients.
• Sjögren's syndrome: Prevalence of Raynaud's in primary Sjögren's ranges from 13 to 33%, according to a meta-analysis published in Autoimmunity Reviews [10].
• Rheumatoid arthritis: Raynaud's occurs in about 10% of RA patients, more commonly in those with vasculitis overlap.

Vascular and Hematologic Causes

Atherosclerosis, thromboangiitis obliterans (Buerger's disease), and thoracic outlet syndrome can produce Raynaud's-like symptoms through mechanical vascular compromise rather than vasospasm. Cryoglobulinemia, cold agglutinin disease, and polycythemia vera trigger episodes through altered blood viscosity or immune complex deposition [11]. These hematologic causes are rare but important to consider when autoimmune serologies come back negative and symptoms are atypical.

Medications and Occupational Exposures

Beta-blockers are the most common drug-induced cause. Non-selective agents (propranolol) carry higher risk than cardioselective ones (metoprolol), though both can trigger episodes. Other culprits include ergotamine derivatives used for migraine, cisplatin and bleomycin in oncology, cyclosporine, interferon-alpha, and sympathomimetic agents including amphetamine-based medications [12].

Occupational vibration exposure causes hand-arm vibration syndrome (HAVS), a well-characterized occupational Raynaud's. Workers using jackhammers, chainsaws, and pneumatic drills are at highest risk. A study of 1,047 forestry workers in Sweden found that 47% developed vibration-induced white finger after 10 or more years of chainsaw use [13]. Vinyl chloride exposure in plastics manufacturing is another occupational trigger, though this is now rare due to industrial regulations.

The Diagnostic Workup: How Clinicians Separate Primary from Secondary

The initial evaluation follows a structured algorithm. The 2017 ACR/EULAR classification criteria for systemic sclerosis and the LeRoy-Medsger criteria for primary Raynaud's together form the diagnostic backbone [5,14].

Step 1: History and Physical Examination

Onset after age 30, asymmetric attacks, digital ulcers or pitting scars, and male sex all raise the probability of secondary disease. The history should cover medication use, occupational exposure, family history of autoimmune disease, and symptoms of connective tissue disease (joint pain, skin tightening, dysphagia, dry eyes and mouth, muscle weakness).

Step 2: Nailfold Capillaroscopy

This non-invasive test uses a dermatoscope or video capillaroscope to examine the nailfold capillaries. Normal capillaries are hairpin-shaped and evenly spaced. In secondary Raynaud's, particularly scleroderma-spectrum disease, the pattern shows enlarged loops, hemorrhages, avascular areas, and disorganized architecture [15]. The sensitivity of nailfold capillaroscopy for detecting scleroderma-spectrum disorders in Raynaud's patients reaches 94%, with specificity around 73%, according to a systematic review in Arthritis Research & Therapy [15].

Dr. Maureen Mayes, a rheumatologist at UTHealth Houston and author of the ACR scleroderma classification criteria, has stated: "Nailfold capillaroscopy is the single most important test we have for triaging Raynaud's patients. An abnormal pattern in a young woman with Raynaud's changes the follow-up interval from years to months" [14].

Step 3: Laboratory Testing

A reasonable first-line panel includes ANA (with reflex to specific antibodies if positive), ESR or CRP, CBC, and basic metabolic panel. ANA is positive in over 90% of systemic sclerosis and SLE cases [9]. Specific antibody patterns narrow the differential:

• Anti-centromere antibody: limited cutaneous systemic sclerosis (CREST syndrome)
• Anti-Scl-70 (anti-topoisomerase I): diffuse cutaneous systemic sclerosis
• Anti-U1 RNP: mixed connective tissue disease
• Anti-dsDNA: systemic lupus erythematosus
• Anti-SSA/SSB: Sjögren's syndrome

If hematologic causes are suspected, cryoglobulins, cold agglutinins, serum protein electrophoresis, and a complete blood count with manual differential are appropriate additions.

Step 4: Vascular Studies

When structural vascular disease is on the differential (asymmetric symptoms, absent pulses, older patients), digital plethysmography, Allen's test, and arterial duplex ultrasound help distinguish fixed obstruction from vasospasm [11]. CT angiography or conventional angiography is reserved for cases where surgical intervention is being considered.

When to Worry: Red Flags That Demand Urgent Evaluation

Not all Raynaud's is benign. Certain features require prompt rheumatology or vascular surgery referral.

Digital ulcers or gangrene indicate severe secondary Raynaud's with tissue ischemia. These patients need aggressive vasodilator therapy and workup for systemic sclerosis. Onset after age 40 with asymmetric symptoms suggests atherosclerotic disease or a paraneoplastic phenomenon. A single-digit Raynaud's presentation (only one finger affected) raises concern for a structural lesion, digital artery thrombosis, or embolic disease [11].

The 2021 British Society for Rheumatology (BSR) guideline on Raynaud's management states clearly: "Patients with Raynaud's who have abnormal nailfold capillaroscopy, positive ANA, or digital ulceration should be referred to a specialist centre and followed prospectively for the development of connective tissue disease" [16]. About 12 to 15% of patients initially diagnosed with primary Raynaud's will develop a definable connective tissue disease within 10 years of follow-up [2].

Weight loss, new-onset Raynaud's in a patient over 50, or abnormal complete blood counts should prompt evaluation for occult malignancy. Paraneoplastic Raynaud's, while uncommon, has been reported with ovarian, lung, and hematologic cancers [11].

Treatment: From Behavioral Modifications to Pharmacotherapy

Treatment intensity should match disease severity. Primary Raynaud's with infrequent, non-disabling attacks may need only behavioral strategies. Secondary Raynaud's with digital ischemia requires pharmacotherapy and often combination regimens.

Non-Pharmacologic Approaches

Cold avoidance is the foundation. Keeping core body temperature warm (not just the hands) reduces peripheral vasospasm. Battery-heated gloves, chemical hand warmers, and layered clothing all have practical value. Smoking cessation is non-negotiable because nicotine directly potentiates digital vasospasm [1]. Stress management techniques, including biofeedback, have shown modest benefit in small trials.

First-Line Pharmacotherapy

Dihydropyridine calcium channel blockers (CCBs) are the evidence-based first-line agents. Nifedipine extended-release (30 to 60 mg daily) is the most studied, reducing attack frequency by approximately 33% and attack severity by 33% in a Cochrane systematic review of 7 randomized controlled trials (N=296) [17]. Amlodipine (5 to 10 mg daily) is an alternative with fewer headache-related side effects.

Second-Line and Advanced Therapies

Phosphodiesterase-5 (PDE-5) inhibitors have accumulated strong evidence, particularly for secondary Raynaud's with digital ulcers. Sildenafil (20 mg three times daily) reduced Raynaud's attack frequency, duration, and severity in a meta-analysis of 6 RCTs published in The Journal of Rheumatology [18]. Tadalafil 20 mg daily is also used off-label with similar effect.

For refractory digital ulcers in systemic sclerosis, intravenous iloprost (a prostacyclin analogue) is the standard in European practice. The RAPIDS-2 trial (N=188) demonstrated that bosentan, an endothelin receptor antagonist, reduced new digital ulcer formation by 48% compared with placebo, though it did not heal existing ulcers [19]. Bosentan received FDA approval specifically for this indication.

Topical nitroglycerin applied to the affected digits provides local vasodilation. A phase III trial of a topical nitroglycerin formulation (MQX-503) showed statistically significant improvement in Raynaud's Condition Score, though the absolute effect size was modest [20].

Botulinum toxin injection into the digital neurovascular bundles has emerged as a treatment for severe, medication-refractory Raynaud's. A systematic review of 6 studies (N=125 hands) reported symptom improvement in over 80% of treated hands, with effects lasting 3 to 12 months [21]. This approach remains off-label and is typically offered at specialized centers.

Surgical Options

Digital sympathectomy, the stripping of the adventitia from digital arteries, is reserved for cases with critical digital ischemia unresponsive to maximal medical therapy. Outcomes are favorable in experienced hands, but recurrence rates of 30 to 40% at 5 years limit enthusiasm for early intervention [11].

The Connection Between Raynaud's and Hormones

Sex hormone differences likely contribute to the 4:1 female predominance. Estrogen modulates vascular tone through endothelium-dependent nitric oxide production and alpha-2 adrenergic receptor expression [1]. Raynaud's attacks often worsen premenstrually and may improve during pregnancy (when estrogen and progesterone levels are high and peripheral vasodilation increases).

Hypothyroidism is an underrecognized secondary cause. A study of 68 patients with primary Raynaud's found that 15% had subclinical hypothyroidism, and thyroid hormone replacement reduced attack frequency in the hypothyroid subgroup [22]. Checking TSH is a reasonable addition to the initial laboratory panel, particularly given the low cost and high treatment yield.

For women on hormone replacement therapy (HRT), the relationship is complex. Some women report improvement in Raynaud's symptoms with estrogen therapy, while others note worsening. The data are insufficient to recommend HRT specifically for Raynaud's, but existing HRT for menopausal symptoms does not need to be discontinued solely because of Raynaud's [1].

Living with Raynaud's: Practical Guidance Beyond the Prescription

Patients benefit from concrete instructions rather than vague advice. Keep indoor thermostat at 68°F or higher. Pre-warm the car before driving in winter. Use insulated beverage holders to avoid cold-triggered attacks when holding drinks. Wear mittens rather than gloves (mittens keep fingers together, sharing warmth). Choose wind-resistant outer layers because wind chill is the primary environmental trigger [16].

Exercise improves peripheral circulation. A small randomized trial (N=26) of 12 weeks of aerobic exercise showed a 19% reduction in Raynaud's attack frequency compared with controls [23]. The mechanism likely involves improved endothelial function and reduced sympathetic tone.

For patients with secondary Raynaud's, the relationship between attack management and disease progression is direct. Each ischemic episode carries cumulative microvascular damage. The BSR guideline recommends a written personalized action plan covering cold protection strategies, early medication use at first color change, and clear criteria for emergency presentation (non-resolving white digit after 30 minutes of rewarming, new ulceration, or sudden single-digit involvement) [16].

Nifedipine 30 mg extended-release taken 30 minutes before anticipated cold exposure is a validated "as-needed" dosing strategy for patients who prefer not to take daily medication during warmer months [17].